- Home
- CRT vs BCAB Comparison
CRT vs BCAB Comparison
Compare CRT & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRT | BCAB |
|---|---|---|
| Founded | 1991 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 71.6M |
| IPO Year | 1992 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRT | BCAB |
|---|---|---|
| Price | $8.05 | $0.80 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 26.5K | ★ 2.1M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 9.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $5,621,913.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.07 | $0.24 |
| 52 Week High | $13.31 | $1.53 |
Technical Indicators
Market Signals| Indicator | CRT | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 41.37 | 47.86 |
| Support Level | $7.91 | $0.79 |
| Resistance Level | $8.36 | $0.90 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 9.28 | 23.68 |
Price Performance
Historical ComparisonAbout CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.